Sophie Piperno‐Neumann
YOU?
Author Swipe
View article: Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients Open
Purpose: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T-cell engager, which can redirect T cells to target glycoprotein 100–positive cells, in metastatic uveal me…
View article: Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres
Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres Open
Tebentafusp is safe for pre-treated and treatment-naive patients with mUM in real-life. Treatment effect was observed in patients treated beyond initial progression. Patients with baseline elevated LDH and extrahepatic metastases had signi…
View article: Management of metastatic uveal melanoma: French expert consensus guidelines
Management of metastatic uveal melanoma: French expert consensus guidelines Open
Uveal melanoma (UM) is a rare malignancy originating from uveal melanocytes. Despite effective control of the primary tumour, metastatic uveal melanoma (MUM) occurs in approximately 20-30% of patients, primarily affecting the liver, with a…
View article: Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France – protocol of a prospective observational mixed-method study
Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France – protocol of a prospective observational mixed-method study Open
NCT06073548 (October 4, 2023).
View article: Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma Open
Combination therapy with doxorubicin and trabectedin induction, followed by trabectedin maintenance, was associated with improved overall survival and progression-free survival, as compared with doxorubicin alone, among patients with metas…
View article: Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial
Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial Open
Metastatic uveal melanoma (UM) patients often initially present with limited symptoms despite a poor prognosis, complicating communication with patients and caregivers. Early Together (NCT04728113) is a randomized Phase III trial that inte…
View article: Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action
Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action Open
Tebentafusp is a gp100xCD3-bispecific ImmTAC designed to redirect polyclonal T cells against cells presenting the melanocyte lineage-specific antigen gp100 on HLA-A∗02:01. Skin-related adverse events, predominantly rash, are frequent and o…
View article: Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement
Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement Open
Osteosarcoma and Ewing sarcoma are bone tumors mostly diagnosed in children, adolescents, and young adults. Despite multimodal therapy, morbidity is high and survival rates remain low, especially in the metastatic disease setting. Trials i…
View article: Facilitating patient-oncologist communication in advanced treatment-resistant cancer: development and feasibility testing of a question prompt list.
Facilitating patient-oncologist communication in advanced treatment-resistant cancer: development and feasibility testing of a question prompt list. Open
Background Patients' expectations regarding medical information in advanced stages of cancer are still poorly understood in France. Tailoring information to advanced cancer patients is a subtle task. We have developed a question prompt lis…
View article: Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience
Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience Open
Background Previous studies have shown that neutrophil‐to‐lymphocyte (NLR) ratio at diagnosis and early lymphocytes recovery on doxorubicin‐based chemotherapy, may impact the outcome in patients with osteosarcoma (OST). This study aimed to…
View article: Divergent local and systemic antitumor response in primary uveal melanomas
Divergent local and systemic antitumor response in primary uveal melanomas Open
Uveal melanoma (UM) is the most common cancer of the eye. The loss of chromosome 3 (M3) is associated with a high risk of metastases. M3 tumors are more infiltrated by T-lymphocytes than low-risk disomic-3 (D3) tumors, contrasting with oth…
View article: Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN Open
About 500,000 patients with rare adult solid cancers (RASC) are diagnosed yearly in Europe. Delays and unequal quality of management impact negatively their survival. Since 2017, European reference networks (ERN) aim to improve the quality…
View article: Improved nationwide survival of sarcoma patients with a network of reference centers
Improved nationwide survival of sarcoma patients with a network of reference centers Open
The implementation of the national reference network for sarcoma was associated with an improvement of overall survival and compliance to guidelines nationwide in sarcoma patients. Referral to expert networks for sarcoma patients should be…
View article: Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis Open
Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM. Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with N+I. These data further…
View article: 187P Local and systemic anti-tumor response during tumor development in an immune privileged site: The case of uveal melanoma
187P Local and systemic anti-tumor response during tumor development in an immune privileged site: The case of uveal melanoma Open
Uveal melanoma (UM), an uncommon but aggressive eye cancer, exhibits genetic diversity, classifying into M3 (poor prognosis) and D3 (better outcome) subsets. Despite low mutation rates, metastatic UM patients have detectable CD4 and CD8 T …
View article: Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma Open
This 3-year analysis supported a continued long-term benefit of tebentafusp for overall survival among adult HLA-A*02:01-positive patients with previously untreated metastatic uveal melanoma. (Funded by Immunocore; IMCgp100-202 ClinicalTri…
View article: Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study Open
Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor, and few treatment options exist. Here, we invest…